Philip Morris International

Philip Morris International (PMI) presented evidence to the FDA’s advisory committee (TPSAC) supporting the continued marketing of IQOS as a modified risk tobacco product (MRTP). PMI seeks to communicate that switching completely to IQOS significantly reduces exposure to harmful chemicals. The FDA previously authorized IQOS as an MRTP, and PMI is seeking approval for IQOS ILUMA. PMI has invested heavily in smoke-free products, aiming to transition smokers away from traditional cigarettes. The FDA’s decision will impact the regulation of next-generation nicotine products.